Lu AG13909

Phase 2

Lundbeck

Lu AG13909 is one of 2 therapeutic programs targeting Cushing's Disease. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Cushing's DiseaseRecruiting

Cushing's DiseasePhase 2

Recruiting

Competition

Competitive Landscape

1 competitor in Cushing's Disease

#DrugCompanyPhaseTrials

Lu AF95245

Lundbeck

Phase 2

1 2

Lu AG13909

Lundbeck

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 2Recruiting

Cushing's Disease

NCT06471829

Clinical

Trials by Indication[1]

Cushing's Disease1 trial

A Phase II, Multi-site, Open-label, Dose-titration Trial to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of Lu AG13909 in Adults With Cushing's Disease

Recruiting· Lundbeck logo

Lundbeck·Phase 2·NCT06471829·18 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Lu AG13909. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Lu AG13909. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Lundbeck company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 2[1]
Company: Lundbeck

Lu AG13909

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Cushing's Disease1 trial

References

Drug Info

Quick Facts

Related News